Estee Lauder tumbled Wednesday as investors focused on the company’s weak fiscal fourth-quarter outlook instead of its strong third-quarter numbers. We’re looking deeper and believe that business fundamentals and profit are set to improve into the next fiscal year. Revenue in the three months ended March 31 advanced 5% year …
Starbucks shares plummeted Tuesday evening by roughly 11.5% after the coffee giant delivered a much weaker-than-expected quarter. The company also cut its outlook for fiscal 2024, leaving little room for optimism of a quick rebound in traffic at its stores. Revenue fell 2% year over year to $8.56 billion in …
Eaton delivered beats on the top and bottom lines on Tuesday but saw its stock slip as investors took profits after a 30% gain so far this year. We see a buying opportunity. Revenue increased 8% year over year organically to a new first-quarter record of $5.94 billion, outpacing analyst …
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in …
Microsoft delivered picture-perfect earnings after the bell Thursday, calming the market’s brief fears about runaway spending on AI infrastructure without the cloud revenues to show for it. Revenue increased about 17% year over year, to $61.86 billion, beating the Street consensus estimate of $60.8 billion, according to data from LSEG. …
Ford Motor on Wednesday evening delivered higher than expected profits in the first quarter, driven by strength in its commercial business. Positive updates to its full-year outlook helped send shares rallying by roughly 2.5% in after-hours trading. Automotive revenue increased 2% year over year, to $38.89 billion, missing analysts’ forecasts …
Abbott Laboratories delivered a top and bottom line beat Wednesday and surprised investors by raising its full-year guidance — a show of confidence by the medical device maker not seen in a first quarter since 2016. Revenue for the three months ended March 31 rose slightly more than 2% year …
